Good interview with Antti. In Inderes’ robo-comment on the Q1 result: “Bioretec’s Q1 revenue was EUR 1.22 million, exceeding the expected EUR 0.85 million, which was due to the rapid commercial progress of the RemeOs product family in Europe and the United States,” and “Sales of RemeOs products grew significantly in key markets, and their share of revenue rose to 60%, which is a significant structural change.” In the H1 interview, Activa has, in Sari’s words, been the predominant source of sales volume in the US.
1 Like